NCT00055692View on ClinicalTrials.gov

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

December 31, 2009

Conditions
Adult Primary Hepatocellular CarcinomaLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver Cancer
Interventions
BIOLOGICAL

bevacizumab

Given orally

Trial Locations (1)

10467-2490

Montefiore Medical Center - Moses Campus, The Bronx

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00055692 - Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer | Biotech Hunter | Biotech Hunter